Cargando…

Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis

BACKGROUND: The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pul...

Descripción completa

Detalles Bibliográficos
Autores principales: Muneeb Hassan, Muhammad, Ameeq, Muhammad, Jamal, Farrukh, Tahir, Muhammad H., Mendy, John T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815254/
https://www.ncbi.nlm.nih.gov/pubmed/36594409
http://dx.doi.org/10.1080/07853890.2022.2160491
_version_ 1784864314449985536
author Muneeb Hassan, Muhammad
Ameeq, Muhammad
Jamal, Farrukh
Tahir, Muhammad H.
Mendy, John T.
author_facet Muneeb Hassan, Muhammad
Ameeq, Muhammad
Jamal, Farrukh
Tahir, Muhammad H.
Mendy, John T.
author_sort Muneeb Hassan, Muhammad
collection PubMed
description BACKGROUND: The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pulmonary disease (COPD), with numerous infections in COVID-19 patients. OBJECTIVES: Priority is placed on determining the patient’s prognosis based on the presence or absence of TB and COPD. Additionally, a comparison is made between the risk of death and the likelihood of recovery in terms of time in COVID-19 patients who have either COPD or TB. METHODOLOGY: At the DHQ Hospital in Muzaffargarh, Punjab, Pakistan, 498 COVID-19 patients with TB and COPD were studied retrospectively. The duration of study started in February 2022 and concluded in August 2022. The Kaplan–Meier curves described time-to-death and time-to-recovery stratified by TB and COPD status. The Wilcoxon test compared the survival rates of people with TB and COPD in two matched paired groups and their status differences with their standard of living. RESULTS: The risk of death in COVID-19 patients with TB was 1.476 times higher than in those without (95% CI: 0.949–2.295). The recovery risk in COVID-19 patients with TB was 0.677 times lower than in those without (95% CI: 0.436–1.054). Similarly, patients with TB had a significantly shorter time to death (p=.001) and longer time to recovery (p=.001). CONCLUSIONS: According to the findings, the most significant contributor to an increased risk of morbidity and mortality in TB and COPD patients was the COVID-19. KEY MESSAGES: SARS-Cov-19 is a new challenge for the universe in terms of prevention and treatment for people with tuberculosis and chronic obstructive pulmonary disease, among other diseases. Propensity score matching to control for potential biases. Compared to hospitalized patients with and without (TB and COPD) had an equivalently higher mortality rate.
format Online
Article
Text
id pubmed-9815254
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-98152542023-01-06 Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis Muneeb Hassan, Muhammad Ameeq, Muhammad Jamal, Farrukh Tahir, Muhammad H. Mendy, John T. Ann Med Infectious Diseases BACKGROUND: The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pulmonary disease (COPD), with numerous infections in COVID-19 patients. OBJECTIVES: Priority is placed on determining the patient’s prognosis based on the presence or absence of TB and COPD. Additionally, a comparison is made between the risk of death and the likelihood of recovery in terms of time in COVID-19 patients who have either COPD or TB. METHODOLOGY: At the DHQ Hospital in Muzaffargarh, Punjab, Pakistan, 498 COVID-19 patients with TB and COPD were studied retrospectively. The duration of study started in February 2022 and concluded in August 2022. The Kaplan–Meier curves described time-to-death and time-to-recovery stratified by TB and COPD status. The Wilcoxon test compared the survival rates of people with TB and COPD in two matched paired groups and their status differences with their standard of living. RESULTS: The risk of death in COVID-19 patients with TB was 1.476 times higher than in those without (95% CI: 0.949–2.295). The recovery risk in COVID-19 patients with TB was 0.677 times lower than in those without (95% CI: 0.436–1.054). Similarly, patients with TB had a significantly shorter time to death (p=.001) and longer time to recovery (p=.001). CONCLUSIONS: According to the findings, the most significant contributor to an increased risk of morbidity and mortality in TB and COPD patients was the COVID-19. KEY MESSAGES: SARS-Cov-19 is a new challenge for the universe in terms of prevention and treatment for people with tuberculosis and chronic obstructive pulmonary disease, among other diseases. Propensity score matching to control for potential biases. Compared to hospitalized patients with and without (TB and COPD) had an equivalently higher mortality rate. Taylor & Francis 2023-01-03 /pmc/articles/PMC9815254/ /pubmed/36594409 http://dx.doi.org/10.1080/07853890.2022.2160491 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Infectious Diseases
Muneeb Hassan, Muhammad
Ameeq, Muhammad
Jamal, Farrukh
Tahir, Muhammad H.
Mendy, John T.
Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title_full Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title_fullStr Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title_full_unstemmed Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title_short Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
title_sort prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815254/
https://www.ncbi.nlm.nih.gov/pubmed/36594409
http://dx.doi.org/10.1080/07853890.2022.2160491
work_keys_str_mv AT muneebhassanmuhammad prevalenceofcovid19amongpatientswithchronicobstructivepulmonarydiseaseandtuberculosis
AT ameeqmuhammad prevalenceofcovid19amongpatientswithchronicobstructivepulmonarydiseaseandtuberculosis
AT jamalfarrukh prevalenceofcovid19amongpatientswithchronicobstructivepulmonarydiseaseandtuberculosis
AT tahirmuhammadh prevalenceofcovid19amongpatientswithchronicobstructivepulmonarydiseaseandtuberculosis
AT mendyjohnt prevalenceofcovid19amongpatientswithchronicobstructivepulmonarydiseaseandtuberculosis